Literature DB >> 20699456

Prevalence of diabetic retinopathy in the United States, 2005-2008.

Xinzhi Zhang1, Jinan B Saaddine, Chiu-Fang Chou, Mary Frances Cotch, Yiling J Cheng, Linda S Geiss, Edward W Gregg, Ann L Albright, Barbara E K Klein, Ronald Klein.   

Abstract

CONTEXT: The prevalence of diabetes in the United States has increased. People with diabetes are at risk for diabetic retinopathy. No recent national population-based estimate of the prevalence and severity of diabetic retinopathy exists.
OBJECTIVES: To describe the prevalence and risk factors of diabetic retinopathy among US adults with diabetes aged 40 years and older. DESIGN, SETTING, AND PARTICIPANTS: Analysis of a cross-sectional, nationally representative sample of the National Health and Nutrition Examination Survey 2005-2008 (N = 1006). Diabetes was defined as a self-report of a previous diagnosis of the disease (excluding gestational diabetes mellitus) or glycated hemoglobin A(1c) of 6.5% or greater. Two fundus photographs were taken of each eye with a digital nonmydriatic camera and were graded using the Airlie House classification scheme and the Early Treatment Diabetic Retinopathy Study severity scale. Prevalence estimates were weighted to represent the civilian, noninstitutionalized US population aged 40 years and older. MAIN OUTCOME MEASUREMENTS: Diabetic retinopathy and vision-threatening diabetic retinopathy.
RESULTS: The estimated prevalence of diabetic retinopathy and vision-threatening diabetic retinopathy was 28.5% (95% confidence interval [CI], 24.9%-32.5%) and 4.4% (95% CI, 3.5%-5.7%) among US adults with diabetes, respectively. Diabetic retinopathy was slightly more prevalent among men than women with diabetes (31.6%; 95% CI, 26.8%-36.8%; vs 25.7%; 95% CI, 21.7%-30.1%; P = .04). Non-Hispanic black individuals had a higher crude prevalence than non-Hispanic white individuals of diabetic retinopathy (38.8%; 95% CI, 31.9%-46.1%; vs 26.4%; 95% CI, 21.4%-32.2%; P = .01) and vision-threatening diabetic retinopathy (9.3%; 95% CI, 5.9%-14.4%; vs 3.2%; 95% CI, 2.0%-5.1%; P = .01). Male sex was independently associated with the presence of diabetic retinopathy (odds ratio [OR], 2.07; 95% CI, 1.39-3.10), as well as higher hemoglobin A(1c) level (OR, 1.45; 95% CI, 1.20-1.75), longer duration of diabetes (OR, 1.06 per year duration; 95% CI, 1.03-1.10), insulin use (OR, 3.23; 95% CI, 1.99-5.26), and higher systolic blood pressure (OR, 1.03 per mm Hg; 95% CI, 1.02-1.03).
CONCLUSION: In a nationally representative sample of US adults with diabetes aged 40 years and older, the prevalence of diabetic retinopathy and vision-threatening diabetic retinopathy was high, especially among Non-Hispanic black individuals.

Entities:  

Mesh:

Year:  2010        PMID: 20699456      PMCID: PMC2945293          DOI: 10.1001/jama.2010.1111

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  36 in total

1.  Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes-the Linköping Diabetes Complications Study.

Authors:  M Nordwall; M Bojestig; H J Arnqvist; J Ludvigsson
Journal:  Diabetologia       Date:  2004-07-02       Impact factor: 10.122

2.  Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

3.  Prevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study.

Authors:  P Mitchell; W Smith; J J Wang; K Attebo
Journal:  Ophthalmology       Date:  1998-03       Impact factor: 12.079

4.  An alternative method of grading diabetic retinopathy.

Authors:  R Klein; B E Klein; Y L Magli; R J Brothers; S M Meuer; S E Moss; M D Davis
Journal:  Ophthalmology       Date:  1986-09       Impact factor: 12.079

5.  Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy.

Authors: 
Journal:  Invest Ophthalmol Vis Sci       Date:  1981-07       Impact factor: 4.799

6.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

7.  The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years.

Authors:  R Klein; B E Klein; S E Moss; M D Davis; D L DeMets
Journal:  Arch Ophthalmol       Date:  1984-04

8.  Cost-effectiveness of detecting and treating diabetic retinopathy.

Authors:  J C Javitt; L P Aiello
Journal:  Ann Intern Med       Date:  1996-01-01       Impact factor: 25.391

9.  Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform.

Authors:  J C Javitt; L P Aiello; Y Chiang; F L Ferris; J K Canner; S Greenfield
Journal:  Diabetes Care       Date:  1994-08       Impact factor: 19.112

10.  The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus.

Authors:  R Klein; B E Klein; S E Moss; K L Linton
Journal:  Ophthalmology       Date:  1992-01       Impact factor: 12.079

View more
  364 in total

1.  Diabetes eye screening in urban settings serving minority populations: detection of diabetic retinopathy and other ocular findings using telemedicine.

Authors:  Cynthia Owsley; Gerald McGwin; David J Lee; Byron L Lam; David S Friedman; Emily W Gower; Julia A Haller; Lisa A Hark; Jinan Saaddine
Journal:  JAMA Ophthalmol       Date:  2015-02       Impact factor: 7.389

Review 2.  Global aetiology and epidemiology of type 2 diabetes mellitus and its complications.

Authors:  Yan Zheng; Sylvia H Ley; Frank B Hu
Journal:  Nat Rev Endocrinol       Date:  2017-12-08       Impact factor: 43.330

Review 3.  Anti-vascular endothelial growth factor therapy for diabetic macular edema.

Authors:  David S Boyer; J Jill Hopkins; Jonathan Sorof; Jason S Ehrlich
Journal:  Ther Adv Endocrinol Metab       Date:  2013-12       Impact factor: 3.565

4.  Diabetic Retinopathy: Focus on Minority Populations.

Authors:  Arpine Barsegian; Boleslav Kotlyar; Justin Lee; Moro O Salifu; Samy I McFarlane
Journal:  Int J Clin Endocrinol Metab       Date:  2017-11-11

Review 5.  A review of anti-VEGF agents for proliferative diabetic retinopathy.

Authors:  P Osaadon; X J Fagan; T Lifshitz; J Levy
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

6.  Angiogenic and Immunologic Proteins Identified by Deep Proteomic Profiling of Human Retinal and Choroidal Vascular Endothelial Cells: Potential Targets for New Biologic Drugs.

Authors:  Justine R Smith; Larry L David; Binoy Appukuttan; Phillip A Wilmarth
Journal:  Am J Ophthalmol       Date:  2018-03-17       Impact factor: 5.258

7.  Machine Learning Approaches for Detecting Diabetic Retinopathy from Clinical and Public Health Records.

Authors:  Omolola Ogunyemi; Dulcie Kermah
Journal:  AMIA Annu Symp Proc       Date:  2015-11-05

Review 8.  Whole exome sequencing identification of novel candidate genes in patients with proliferative diabetic retinopathy.

Authors:  Cindy Ung; Angie V Sanchez; Lishuang Shen; Samaneh Davoudi; Tina Ahmadi; Daniel Navarro-Gomez; Ching J Chen; Heather Hancock; Alan Penman; Suzanne Hoadley; Mark Consugar; Carlos Restrepo; Vinay A Shah; Joseph F Arboleda-Velasquez; Lucia Sobrin; Xiaowu Gai; Leo A Kim
Journal:  Vision Res       Date:  2017-05-09       Impact factor: 1.886

9.  Teleretinal screening for diabetic retinopathy in six Los Angeles urban safety-net clinics: final study results.

Authors:  Omolola Ogunyemi; Sheba George; Lauren Patty; Senait Teklehaimanot; Richard Baker
Journal:  AMIA Annu Symp Proc       Date:  2013-11-16

Review 10.  Fenofibrate and Diabetic Retinopathy.

Authors:  Jared E Knickelbein; Akshar B Abbott; Emily Y Chew
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.